Latest Period
Q1 2026
Security Snapshot
Evommune, Inc. - Common Stock, $0.0001 par value per share (EVMN) Institutional Ownership
CUSIP: 30054Y107
13F Institutional Holders and Ownership History from Q4 2025 to Q1 2026
Institutions Reporting
84
Shares (Excl. Options)
34,576,739
Price
$22.99
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- EVMN on NYSE
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 34,576,739
- Total 13F value
- $793,406,919
- Portfolio coverage rank
- 0%
- Share change
- +7,040,143
- Value change
- +$167,246,545
- Number of holders
- 84
- Shares outstanding
- 35,974,918
- SEC-reported price per share
- $22.69
- Insider filing price
- $22.69
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- EVMN - Evommune, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 30054Y107.
- 84 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 59 to 84 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $465,685,578 to $793,406,919.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 84 institutions filings for Q1 2026.
Security key
30054Y107
Latest holder period
Q1 2026
13F holders
84
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
EVMN full holder history
Evommune, Inc. SEC filings
Evommune, Inc. company facts
Evommune, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 30054Y107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
EVMN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| LSP 7 Cooperative UA | 15% | -6.2% | $114,491,976 | +$7,765,422 | 5,288,313 | +7.3% | LSP 7 Cooperatieve U.A. | 12 Feb 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 9.7% | -12% | $70,347,063 | +$722,023 | 3,494,638 | +1% | RA Capital Management, L.P. | 12 Feb 2026 |
| Pivotal bioVenture Partners Fund I, L.P. | 11% | $69,158,608 | 3,435,599 | Nan Fung Group Holdings Limited | 31 Dec 2025 | |||
| Andera Partners | 6% | 1,897,362 | Andera Partners | 07 Nov 2025 |
As of 31 Mar 2026, 84 institutional investors reported holding 34,576,739 shares of Evommune, Inc. - Common Stock, $0.0001 par value per share (EVMN). This represents 96% of the company’s total 35,974,918 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
84%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 14% | 4,929,633 | 0% | 11% | $113,332,263 |
| RA CAPITAL MANAGEMENT, L.P. | 9.7% | 3,494,638 | +1% | 0.85% | $80,341,728 |
| Pivotal bioVenture Partners Investment Advisor LLC | 5.4% | 1,926,943 | 0% | 16% | $44,300,420 |
| ANDERA PARTNERS | 5.3% | 1,897,362 | 0% | 25% | $43,620,352 |
| RTW INVESTMENTS, LP | 4.2% | 1,502,235 | +17% | 0.34% | $34,536,383 |
| JPMORGAN CHASE & CO | 4.1% | 1,459,420 | +11% | 0% | $32,107,240 |
| MPM BIOIMPACT LLC | 4% | 1,455,863 | +1188% | 2.6% | $33,470,290 |
| Nan Fung Group Holdings Ltd | 4% | 1,441,032 | 0% | 27% | $33,129,326 |
| SymBiosis Capital Partners, LLC | 3.6% | 1,280,778 | 0% | 56% | $29,445,086 |
| EVENTIDE ASSET MANAGEMENT, LLC | 3.4% | 1,209,129 | +26% | 0.46% | $27,797,876 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.1% | 1,119,021 | +43% | 0% | $25,727,000 |
| JANUS HENDERSON GROUP PLC | 2.5% | 896,700 | 0.01% | $20,615,133 | |
| MARSHALL WACE, LLP | 2.4% | 879,728 | -11% | 0.02% | $20,224,946 |
| BAKER BROS. ADVISORS LP | 2.4% | 847,390 | 0.11% | $19,481,496 | |
| Alyeska Investment Group, L.P. | 2% | 726,362 | 0.05% | $16,699,062 | |
| Defilade Capital Management, L.P. | 1.9% | 678,589 | +215% | 2.4% | $15,600,761 |
| BlackRock, Inc. | 1.9% | 673,571 | +373% | 0% | $15,485,397 |
| Kynam Capital Management, LP | 1.7% | 625,496 | +237% | 0.91% | $14,380,153 |
| SECTORAL ASSET MANAGEMENT INC | 1.6% | 589,005 | 0% | 11% | $13,541,225 |
| Verition Fund Management LLC | 1.5% | 549,991 | -2.7% | 0.12% | $12,644,293 |
| AMERICAN CENTURY COMPANIES INC | 1.4% | 492,938 | +18% | 0.01% | $11,332,687 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.3% | 455,051 | 0% | 0% | $10,461,622 |
| PERCEPTIVE ADVISORS LLC | 1.2% | 448,350 | 0.2% | $10,307,567 | |
| Velan Capital Investment Management LP | 1.2% | 446,255 | -12% | 6.4% | $10,259,402 |
| Freestone Grove Partners LP | 0.94% | 337,291 | 0.06% | $7,754,320 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Latest
Q1 2026
Rows shown
1-2 of 2